UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mg2NiH4 synthesis and decomposition reactions

International journal of hydrogen energy, 2013-04, Vol.38 (10), p.4003-4010

2013

Volltextzugriff (PDF)

Synthesis and decomposition mechanisms of ternary Mg2CoH5 studied using in situ synchrotron X-ray diffraction

International journal of hydrogen energy, 2011-08, Vol.36 (17), p.10760-10770

2011

Volltextzugriff (PDF)

Spectroscopy and Photophysics of Monoazaphenanthrenes I. Absorption and Fluorescence Spectra of Phenanthridine and 7,8-Benzoquinoline

Acta physica Polonica, A, 2003-11, Vol.104 (5), p.425-439

2003

Volltextzugriff (PDF)

Spectroscopy and Photophysics of Monoazaphenanthrenes III. Luminescence of Phenanthridine and 7,8-benzoquinoline in Crystalline State

Acta physica Polonica, A, 2004-07, Vol.106 (1), p.77-94

2004

Volltextzugriff (PDF)

Synthesis and decomposition mechanisms of ternary Mg 2CoH 5 studied using in situ synchrotron X-ray diffraction

International journal of hydrogen energy, 2011, Vol.36 (17), p.10760-10770

2011

Volltextzugriff (PDF)

Synthesis and decomposition mechanisms of ternary Mg sub(2CoH) sub(5) studied using in situ synchrotron X-ray diffraction

International journal of hydrogen energy, 2011-08, Vol.36 (17), p.10760-10770

2011

Volltextzugriff (PDF)

Silver nanoparticles in titanium dioxide host plasmonic absorbers

2016 18th International Conference on Transparent Optical Networks (ICTON), 2016, p.1-1

2016

Volltextzugriff (PDF)

Fabrication and Luminescence of Anodic Alumina with Incorporated Vanadyl Citrate Chelate Anions

Journal of Materials Science and Nanotechnology, 2014-08, Vol.1 (1)

2014

Volltextzugriff (PDF)

Morphology and Transport Rates of Mixed IV–VI Compounds in Micro‐Gravity

Journal of the Electrochemical Society, 1977-07, Vol.124 (7), p.1095-1102

1977

Volltextzugriff (PDF)

α‑Amino Acids as Reducing and Capping Agents in Gold Nanoparticles Synthesis Using the Turkevich Method

Langmuir, 2023-06, Vol.39 (25), p.8646-8657

2023

Volltextzugriff (PDF)

Recent Progress in the Fabrication of Photonic Crystals Based on Porous Anodic Materials

Energies (Basel), 2023-05, Vol.16 (10), p.4032

2023

Volltextzugriff (PDF)

RVX-297- a novel BD2 selective inhibitor of BET bromodomains

Biochemical and biophysical research communications, 2016-08, Vol.477 (1), p.62-67

2016

Volltextzugriff (PDF)

A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Clinical cancer research, 2020-10, Vol.26 (20), p.5338-5347

2020

Volltextzugriff (PDF)

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Blood, 2023-11, Vol.142 (Supplement 1), p.3380-3380

2023

Volltextzugriff (PDF)

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease

Atherosclerosis, 2016-04, Vol.247, p.48-57

2016

Volltextzugriff (PDF)

Enzootiology of Trypanosoma evansi in Pantanal, Brazil

Veterinary parasitology, 2004-11, Vol.125 (3), p.263-275

2004

Volltextzugriff (PDF)

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Blood, 2022-11, Vol.140 (Supplement 1), p.4440-4441

2022

Volltextzugriff (PDF)

Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.2739-2739

2021

Volltextzugriff (PDF)

A Phase 2 Trial of Daratumumab and Pembrolizumab in Refractory Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.2-2

2020

Volltextzugriff (PDF)

Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study

Blood, 2022-11, Vol.140 (Supplement 1), p.10534-10536

2022

Volltextzugriff (PDF)

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.19-20

2020

Volltextzugriff (PDF)

OA-57 Results of a Phase 1 Clinical Trial of Belantamab Mafadotin (BelMaf) Combined With Carfilzomib, Lenalidomide, and Dexamethasone (KRd) for Multiple Myeloma (MM) After One Prior Line of Therapy (LOT)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S36-S36

2024

Volltextzugriff (PDF)

A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1023-1023

2022

Volltextzugriff (PDF)

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.38-39

2020

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(49)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Mg2NiH4 synthesis and decomposition reactions

Synthesis and decomposition mechanisms of ternary Mg2CoH5 studied using in situ synchrotron X-ray diffraction

Spectroscopy and Photophysics of Monoazaphenanthrenes I. Absorption and Fluorescence Spectra of Phenanthridine and 7,8-Benzoquinoline

Spectroscopy and Photophysics of Monoazaphenanthrenes III. Luminescence of Phenanthridine and 7,8-benzoquinoline in Crystalline State

Synthesis and decomposition mechanisms of ternary Mg 2CoH 5 studied using in situ synchrotron X-ray diffraction

Synthesis and decomposition mechanisms of ternary Mg sub(2CoH) sub(5) studied using in situ synchrotron X-ray diffraction

Silver nanoparticles in titanium dioxide host plasmonic absorbers

Fabrication and Luminescence of Anodic Alumina with Incorporated Vanadyl Citrate Chelate Anions

Morphology and Transport Rates of Mixed IV–VI Compounds in Micro‐Gravity

α‑Amino Acids as Reducing and Capping Agents in Gold Nanoparticles Synthesis Using the Turkevich Method

Recent Progress in the Fabrication of Photonic Crystals Based on Porous Anodic Materials

RVX-297- a novel BD2 selective inhibitor of BET bromodomains

A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease

Enzootiology of Trypanosoma evansi in Pantanal, Brazil

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

A Phase 2 Trial of Daratumumab and Pembrolizumab in Refractory Multiple Myeloma

Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

OA-57 Results of a Phase 1 Clinical Trial of Belantamab Mafadotin (BelMaf) Combined With Carfilzomib, Lenalidomide, and Dexamethasone (KRd) for Multiple Myeloma (MM) After One Prior Line of Therapy (LOT)

A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Suchergebnisse filtern